KR20220130253A - 안정한 글루코코르티코이드 제제 - Google Patents

안정한 글루코코르티코이드 제제 Download PDF

Info

Publication number
KR20220130253A
KR20220130253A KR1020227031562A KR20227031562A KR20220130253A KR 20220130253 A KR20220130253 A KR 20220130253A KR 1020227031562 A KR1020227031562 A KR 1020227031562A KR 20227031562 A KR20227031562 A KR 20227031562A KR 20220130253 A KR20220130253 A KR 20220130253A
Authority
KR
South Korea
Prior art keywords
formulation
less
months
formulations
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227031562A
Other languages
English (en)
Korean (ko)
Inventor
테레사 데이셔
아달베르트 잘지나
이안 덩컨
Original Assignee
에이브이엠 바이오테크놀로지, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이브이엠 바이오테크놀로지, 엘엘씨 filed Critical 에이브이엠 바이오테크놀로지, 엘엘씨
Publication of KR20220130253A publication Critical patent/KR20220130253A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020227031562A 2018-11-14 2019-11-14 안정한 글루코코르티코이드 제제 Ceased KR20220130253A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862767448P 2018-11-14 2018-11-14
US62/767,448 2018-11-14
KR1020207017795A KR102444113B1 (ko) 2018-11-14 2019-11-14 안정한 글루코코르티코이드 제제
PCT/US2019/061363 WO2020102474A1 (en) 2018-11-14 2019-11-14 Stable glucocorticoid formulation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207017795A Division KR102444113B1 (ko) 2018-11-14 2019-11-14 안정한 글루코코르티코이드 제제

Publications (1)

Publication Number Publication Date
KR20220130253A true KR20220130253A (ko) 2022-09-26

Family

ID=68808595

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227031562A Ceased KR20220130253A (ko) 2018-11-14 2019-11-14 안정한 글루코코르티코이드 제제
KR1020207017795A Active KR102444113B1 (ko) 2018-11-14 2019-11-14 안정한 글루코코르티코이드 제제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207017795A Active KR102444113B1 (ko) 2018-11-14 2019-11-14 안정한 글루코코르티코이드 제제

Country Status (13)

Country Link
US (1) US20200289650A1 (enExample)
EP (1) EP3706721A1 (enExample)
JP (2) JP7337060B2 (enExample)
KR (2) KR20220130253A (enExample)
CN (1) CN111918645A (enExample)
AU (1) AU2019378874B2 (enExample)
BR (1) BR112021009365A2 (enExample)
CA (1) CA3118505A1 (enExample)
EA (1) EA202191345A1 (enExample)
IL (1) IL283199A (enExample)
MX (1) MX2021005665A (enExample)
SG (1) SG11202104702VA (enExample)
WO (1) WO2020102474A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116789728A (zh) * 2023-06-16 2023-09-22 山东斯瑞药业有限公司 一种降低糖皮质激素原料药重金属元素杂质含量的工艺
CN116807970A (zh) * 2023-07-26 2023-09-29 遂成药业股份有限公司 一种地塞米松磷酸钠注射液及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136607A (en) * 1995-11-02 2000-10-24 Bayer Corporation Multi-analyte reference solutions with stable pO2 in zero headspace containers
US20040197333A1 (en) * 2000-02-10 2004-10-07 Cornell Research Foundation, Inc. Use of TGF-beta antagonists to inhibit tumor cell formation or progression
US9694103B2 (en) * 2003-04-16 2017-07-04 The Children's Hospital Of Philadelphia Photochemical activation of surfaces for attaching biomaterial
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
JP4598484B2 (ja) * 2004-11-11 2010-12-15 テルモ株式会社 塩酸リトドリン注射液製剤
JP5111117B2 (ja) * 2005-12-22 2012-12-26 興和株式会社 ステロイドの経時的安定性が改善された外用製剤
AU2013200089B2 (en) * 2006-02-09 2016-03-03 Santen Pharmaceutical Co., Ltd Stable formulations, and methods of their preparation and use
EP2249801A2 (en) * 2008-02-07 2010-11-17 Amgen Inc. Stabilized protein compositions
CN101623291B (zh) 2008-07-07 2011-12-07 天津金耀集团有限公司 一种地塞米松磷酸钠注射液
EP2365812A4 (en) * 2008-11-10 2012-05-16 Nitric Biotherapeutics Inc PHARMACEUTICAL FORMULATIONS FOR THE IONTOPHORETIC DELIVERY OF A CORTICOSTEROID
JP2011136973A (ja) * 2009-12-28 2011-07-14 Keiki Imoto 安定なエダラボン含有水性製剤
GB2477545B (en) * 2010-02-05 2011-12-21 Special Products Ltd A liquid morphine composition for buccal administration
EP3530274A1 (en) 2010-08-18 2019-08-28 Theresa Deisher Dexamethasone to reduce stem cell accumulation in the spleen
ITMI20122002A1 (it) 2012-11-26 2014-05-27 Farmacologico Milanese Srl Lab Preparazioni farmaceutiche liquide stabilizzate
JP6741286B2 (ja) * 2013-03-28 2020-08-19 テルモ株式会社 包装されたアセトアミノフェン注射液製剤の製造方法
KR101485243B1 (ko) * 2013-05-08 2015-01-21 씨제이헬스케어 주식회사 안정화된 페메트렉시드 제제
GR1008921B (el) 2015-12-10 2017-01-12 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση περιεχον δεξαμεθαζονη
JP6748221B2 (ja) 2017-04-01 2020-08-26 エーブイエム・バイオテクノロジー・エルエルシー 細胞免疫療法前の細胞毒性プレコンディショニングの代替
CN107375200A (zh) 2017-06-16 2017-11-24 北京立时达药业有限公司 一种地塞米松磷酸钠注射液及其制备方法
EP3488851A1 (en) * 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies

Also Published As

Publication number Publication date
IL283199A (en) 2021-06-30
AU2019378874A1 (en) 2021-06-17
JP2023116498A (ja) 2023-08-22
EA202191345A1 (ru) 2021-10-08
US20200289650A1 (en) 2020-09-17
JP7337060B2 (ja) 2023-09-01
AU2019378874B2 (en) 2025-05-29
EP3706721A1 (en) 2020-09-16
KR20200111675A (ko) 2020-09-29
CA3118505A1 (en) 2020-05-22
KR102444113B1 (ko) 2022-09-19
MX2021005665A (es) 2021-09-23
JP2021514934A (ja) 2021-06-17
SG11202104702VA (en) 2021-06-29
BR112021009365A2 (pt) 2021-08-10
CN111918645A (zh) 2020-11-10
WO2020102474A1 (en) 2020-05-22

Similar Documents

Publication Publication Date Title
AU2011281035B2 (en) Acetycysteine compositions and methods of use thereof
CN115209882A (zh) 用大麻二酚与依维莫司治疗结节性硬化复合症的方法
US20230285563A1 (en) Formulations of bendamustine
CN106659711A (zh) 呈现长期稳定性的褪黑素注射剂的持久制剂
CN110996910A (zh) 抑郁障碍的治疗
KR102444113B1 (ko) 안정한 글루코코르티코이드 제제
EP2735305B1 (en) Stabilised liquid pharmaceutical preparations
Lee et al. Sickle cell disease in the new era: advances in drug treatment
US11925608B2 (en) Stabilization of epinephrine formulations
WO2020041574A1 (en) Use of gaboxadol in the treatment of gastrointestinal tract disorders and asthma
EP4259100A1 (en) Materials and methods for treating viral and other medicinal conditions
JP2018516890A (ja) がん治療のためのカバジタキセルおよびその使用
KR20220018959A (ko) 6,8-비스-벤질티오-옥타노산을 사용한 림프종 치료를 위한 치료 방법 및 조성물
US20230241218A1 (en) Formulations of bendamustine
KR20250099117A (ko) 도파민을 포함하는 약학적 주사용액
CA3244102A1 (en) STABLE FORMULATIONS CONTAINING THIOTEPA
CN119136818A (zh) 用于早产婴儿的联合疗法
HK40027257A (en) Treatment of depressive disorders

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220913

Application number text: 1020207017795

Filing date: 20200619

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20221104

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230217

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20231208

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230217

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I